LNTH News and Press, Lantheus Holdings Inc. From 08/03/23

2023-08-03 16:16:02 ET Lantheus Holdings, Inc. (LNTH) Q2 2023 Earnings Conference Call August 03, 2023 08:00 AM ET Company Participants Mark Kinarney - Vice President of Investor Relations Mary Anne Heino - Chief Executive Officer Paul Blanchfield - President ...

2023-08-03 09:05:43 ET Aravive ( ARAV ) -58% announces top-line results from phase 3 AXLerate-OC study of batiraxcept in patinum-resistant ovarian cancer. Vicarious Surgical ( RBOT ) -41% on pricing $45M offering . DXC Technology Company ( DXC ) -24% ...

2023-08-03 08:13:29 ET Lantheus Holdings ( NASDAQ: LNTH ) announced a divestiture of the sales-based royalty rights of its opioid antagonist RELISTOR. The company said the sale of this non-core asset allows it to focus on the core radiopharmaceutical business. HealthCare R...

2023-08-03 07:16:38 ET Lantheus press release ( NASDAQ: LNTH ): Q2 Non-GAAP EPS of $1.54 beats by $0.23 . Revenue of $321.7M (+43.8% Y/Y) beats by $15.04M . For further details see: Lantheus Non-GAAP EPS of $1.54 beats by $0.23, revenue of $321.7M beats b...

BEDFORD, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians...

Worldwide revenue of $321.7 million for the second quarter 2023, representing an increase of 43.8% from the prior year period GAAP net income of $94.1 million for the second quarter 2023, compared to GAAP net income of $43.1 million in the prior year period GAAP fully diluted net ...

2023-08-02 16:12:02 ET Lantheus ( NASDAQ: LNTH ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is $1.31 (+47.2% Y/Y) and the consensus Revenue Estimate is $306.66M (+37.1% Y/Y). Over the last 2 year...

2023-08-01 00:23:22 ET Summary POINT Biopharma has two therapies in Phase 3 development with fast track designation, which creates the potential for positive catalysts as early as this year. Positive results from the Phase 2 study of PNT2002 provide optimism for successful results...

BEDFORD, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 3, 2023, to discuss its financial and operating results for the second qua...

2023-06-18 03:54:38 ET Summary Lantheus is growing revenue and earnings at an above-average pace. The strong pipeline of Phase 3 compounds can sustain growth for multiple years. The attractive low valuation and strong growth makes it likely that Lantheus' stock outperforms ove...